Related Experiment Video
Updated: Jan 14, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Agreement Between Self-Reported Antirheumatic Medications and Pharmaceutical Claims in an Australian Inflammatory
Tom Lynch1, Claire Barrett2, Rachel Black3
1Sydney Musculoskeletal Health, Kolling Institute, Faculty of Medicine and Health, The University of Sydney and the Northern Sydney Local Health District and Florance and Cope Professorial Department of Rheumatology, Royal North Shore Hospital, Sydney, New South Wales, Australia.
Objective:
To assess agreement between prescription claims data and self-reported medication use via longitudinal questionnaires in the Australian Rheumatology Association Database inflammatory arthritis cohort and to identify predictors of discordant self-reports.
Methods:
Agreement was determined between longitudinal questionnaire self-reports (2012-2023) of disease-modifying antirheumatic drug (DMARD), glucocorticoid, anti-inflammatory, and analgesic use and Australian reference standard prescription medication dispensing data (Pharmaceutical Benefits Scheme) using Cohen's kappa, sensitivity, positive predictive value (PPV), and negative predictive value (NPV). Analyses were repeated using four look-back windows of dispensing data (1, 3, 6, and 12 months) before each questionnaire to characterize variations in agreement metrics at the individual medication level. Predictors of discordant self-reports were explored using multivariable logistic regression.
Results:
In our study population (N = 3,407, 67% female, 93.7% White, 64.4% with rheumatoid arthritis, 18.5% with psoriatic arthritis, 14.6% with ankylosing spondylitis, 2.6% with juvenile idiopathic arthritis), agreement with prescription claims data was substantial to high for DMARDs (κ 0.67-0.95, sensitivity 0.69-0.96, PPV 0.64-0.96, NPV 0.9-1), substantial for prescription-only nonopioid analgesics and oral prednisolone/prednisone (κ 0.66-0.80, sensitivity 0.65-0.88, PPV 0.68-0.77, NPV 0.93-1), and moderate to substantial for prescription-only opioid analgesics (κ 0.48-0.7, sensitivity 0.57-0.74, PPV 0.36-0.69, NPV 0.94-1). A 3-month look-back window optimized agreement for most medications, whereas 6- and 12-month windows further improved agreement for specific drugs. No consistent predictors of discordant self-reports were identified, though greater self-rated disability severity and poorer overall health showed the most consistent associations with discordance.
Conclusion:
Agreement between self-reported and pharmaceutical claims data was moderate to high. Poorer overall health and disability may impact accuracy of medication self-report.
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Antihypertensive Drugs: Direct Renin Inhibitors
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

